Clinician’s Guide to Prevention and Treatment of Osteoporosis
Open accessThe DOI matches its Crossref record; 101 of the 102 references it cites were found in a registry or an index; 41 of the 169 sources its claims cite were checked for support.
Abstract
The Clinician's Guide to Prevention and Treatment of Osteoporosis was developed by an expert committee of the National Osteoporosis Foundation (NOF) in collaboration with a multispecialty council of medical experts in the field of bone health convened by NOF. Readers are urged to consult current prescribing information on any drug, device, or procedure discussed in this publication.
Overview
CoChat Summary
TL;DR
This NOF Clinician’s Guide provides recommendations for prevention, risk assessment, diagnosis, and treatment of osteoporosis in postmenopausal women and men age 50 and older, including BMD testing, vertebral imaging, FRAX-based intervention thresholds, and FDA-approved pharmacotherapy. It emphasizes that osteoporosis is common, underdiagnosed, and treatable, with treatment thresholds and drug-specific fracture risk reductions summarized.
Key findings
- Osteoporosis affects more than 9.9 million Americans, with an additional 43.1 million having low bone density; about 1 in 2 Caucasian women and approximately 1 in 5 men will experience an osteoporosis-related fracture. Annually, 2 million fractures are attributed to osteoporosis, causing more than 432,000 hospital admissions, almost 2.5 million medical office visits, and about 180,000 nursing home admissions; costs are expected to rise to $25.3 billion by 2025. Only 23% of women age 67 or older who have an osteoporosis-related fracture receive either a BMD test or a prescription for osteoporosis drug in the 6 months after fracture.
- Pharmacologic treatment is recommended for hip or vertebral fracture, T-score ≤−2.5 at the femoral neck, total hip, or lumbar spine, or low bone mass (T-score between −1.0 and −2.5) with a 10-year hip fracture probability ≥3% or a 10-year major osteoporosis-related fracture probability ≥20% by US-adapted FRAX.
- Universal recommendations include calcium intake of 1000 mg/day for men 50–70 and 1200 mg/day for women 51 and older and men 71 and older; vitamin D 800–1000 IU/day for adults age 50 and older; regular weight-bearing and muscle-strengthening exercise; fall risk assessment and modification; smoking cessation; and avoidance of excessive alcohol.
- Selected drug efficacy data: alendronate reduces spine and hip fractures by about 50% over 3 years; zoledronic acid reduces vertebral fractures by 70%, hip fractures by 41%, and nonvertebral fractures by 25% over 3 years; denosumab reduces vertebral fractures by about 68%, hip fractures by about 40%, and nonvertebral fractures by about 20% over 3 years; teriparatide reduces vertebral fractures by about 65% and nonvertebral fragility fractures by about 53%; raloxifene reduces vertebral fractures by about 30% with prior vertebral fracture and about 55% without; calcitonin reduces vertebral fracture occurrence by about 30% but has not been shown to reduce nonvertebral fractures; ibandronate reduces vertebral fractures by about 50% but nonvertebral fracture reduction has not been documented.
Methods
- Design: guideline developed by an expert committee of the National Osteoporosis Foundation in collaboration with a multispecialty council of medical experts in bone health; recommendations apply to postmenopausal women and men age 50 and older.
- Data or sample: no primary study sample; the Guide synthesizes evidence including NHANES III prevalence estimates, the Women’s Health Initiative, FDA prescribing information, WHO FRAX, and cost-effectiveness analyses.
- Main analysis: expert consensus and evidence synthesis; absolute risk thresholds for pharmacologic intervention were guided by a cost-effectiveness analysis; diagnostic assessment uses central DXA, vertebral imaging, and US-adapted WHO FRAX.
Limitations
- Stated: FRAX underestimates fracture risk in patients with recent fractures, multiple osteoporosis-related fractures, and increased fall risk; it has not been validated for lumbar spine BMD, is not intended for younger adults or children, and has not been validated in patients currently or previously treated with osteoporosis pharmacotherapy.
- Stated: evidence of efficacy beyond 5 years is limited; rare safety concerns such as osteonecrosis of the jaw and atypical femur fractures become more common beyond 5 years; there are relatively few data confirming fracture risk reductions with pharmacotherapy in patients selected by low bone mass plus FRAX thresholds; fracture data are limited in glucocorticoid-induced osteoporosis and in men; and in the absence of head-to-head trials, direct comparisons of risk reduction among drugs should be avoided.
- Evident: the text does not report a systematic search strategy or formal evidence-grading system; the therapeutic thresholds are described as clinical guidance only and “not rules,” requiring individualized clinical judgment.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Micrographs of normal vs. osteoporotic bone [9], from Dempster et al., with permission of The American Society for Bone and Mineral Research [9]](https://figures.cochat.ai/paper-figures/d609b75c87444980afa9b5aebc701061/clinicians-guide-to-prevention-and-treatment-of-osteoporosis-figure-1.jpg)
![Fig. 2 Pathogenesis of osteoporosis-related fractures, from Cooper and Melton, with modification [10]](https://figures.cochat.ai/paper-figures/ff3ff2f3f4b84a5bbd00a8cc79080d62/clinicians-guide-to-prevention-and-treatment-of-osteoporosis-figure-2.jpg)

Verification
Claims the paper makes
29 Valid · 18 Not valid · 68 Not checked · 17 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Raloxifene is also indicated for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis [83–86].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Pharmacologic therapy > Estrogen agonist/antagonist (formerly known as SERMs): Raloxifene
What the sources say
- Not checked — no full text of the sourcecites [83] Cauley JA Norton L Lippman ME Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation Breast Cancer Res Treat 2001 65 2 125 134 10.1023/A:1006478317173 11261828 source
- Disputedcites [84] Martino S Cauley JA Barrett-Connor E CORE Investigators Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene J Natl Cancer Inst 2004 96 23 1751 1761 10.1093/jnci/djh319 15572757 sourceExperimental — accuracy not yet measured
The introduction (p. 1) says raloxifene was approved for preventing and treating postmenopausal osteoporosis, while tamoxifen was the only agent approved in the United States to reduce breast cancer incidence. Although the CORE results (p. 5) show reduced invasive breast cancer incidence with raloxifene, they do not support the claim that breast cancer risk reduction was an approved indication. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [85] Vogel VG Costantino JP Wickerham DL National Surgical Adjuvent Breast and Bowel Project (NSABP) Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial JAMA 2006 295 23 2727 2741 10.1001/jama.295.23.joc60074 16754727 source
- Partly supportedcites [86] Barrett-Connor E Mosca L Collins P Raloxifene Use for The Heart (RUTH) Trial Investigators Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women N Engl J Med 2006 355 2 125 137 10.1056/NEJMoa062462 16837676 sourceExperimental — accuracy not yet measured
The Primary Outcomes (p. 5) report that raloxifene reduced invasive breast cancer in the RUTH trial, and the introductory text (p. 2) reports a similar finding from MORE, an osteoporosis-treatment trial. The paper does not state that breast-cancer risk reduction is an approved indication for postmenopausal women with osteoporosis; RUTH enrolled women with or at increased risk for coronary heart disease. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Ibandronate reduces the incidence of vertebral fractures by about 50 % over 3 years, but reduction in risk of nonvertebral fracture with ibandronate has not been documented [50].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Pharmacologic therapy > Bisphosphonates
What the sources say
- Disputedcites [50] Chesnut CH 3rd Skag A Christiansen C Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis J Bone Miner Res 2004 19 18 1241 1249 10.1359/JBMR.040325 15231010 sourceExperimental — accuracy not yet measured
The Clinical osteoporotic nonvertebral fractures section reports a statistically significant 69% reduction with daily ibandronate in women with a baseline femoral-neck BMD T score below −3.0. The Discussion cautions that this was a post hoc analysis and says there was no significant reduction in the overall population, but the unqualified claim that a reduction has not been documented overlooks the reported subgroup finding. Page numbers were not provided in the supplied passages. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A vertebral fracture is consistent with a diagnosis of osteoporosis, even in the absence of a bone density diagnosis, and is an indication for pharmacologic treatment with osteoporosis medication to reduce subsequent fracture risk [18, 21].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Vertebral imaging
What the sources say
- Not checked — no full text of the sourcecites [18] Kanis JA Melton LJ 3rd Christiansen C Johnston CC Khaltaev N The diagnosis of osteoporosis J Bone Miner Res 1994 9 8 1137 1141 10.1002/jbmr.5650090802 7976495 source
- Supportedcites [21] Melton LJ Chrischilles EA Cooper C Lane AW Riggs BL How many women have osteoporosis? J Bone Miner Res 2005 20 5 886 892 10.1359/jbmr.2005.20.5.886 15931736 source
The conclusion (OSTEOPENIA, p. 6) distinguishes osteoporosis assessed by bone mineral measurements from established osteoporosis assessed by the occurrence of specific fractures. The introduction (p. 2) identifies vertebral fractures among the principal osteoporosis-related fractures, supporting the stated diagnosis without a bone-density diagnosis. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Help determine adequacy of patient compliance and persistence with osteoporosis therapy”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Biochemical markers of bone turnover
What the sources say
- Partly supportedcites [25] Burch J Rice S Yang H Neilson A Stirk L Francis R Holloway P Selby P Craig D Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups Health Technol Assess (Winchester, England) 2014 18 11 1 206 PMC4781229 24534414 sourceExperimental — accuracy not yet measured
The review’s “Compliance and persistence” section describes a model in which a bone turnover marker result could lead to a conclusion that compliance or treatment response was inadequate, but notes that the model did not include test-accuracy data. “Measures of adherence” says that a marker-identified non-response could reflect non-compliance or non-persistence, among several other causes. The source therefore supports markers as a possible clue, not as a way to determine the adequacy of both compliance and persistence. (LLM, conf=0.83)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Predict magnitude of BMD increases with FDA-approved therapies”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Biochemical markers of bone turnover
What the sources say
- Partly supportedcites [25] Burch J Rice S Yang H Neilson A Stirk L Francis R Holloway P Selby P Craig D Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups Health Technol Assess (Winchester, England) 2014 18 11 1 206 PMC4781229 24534414 sourceExperimental — accuracy not yet measured
The Clinical Effectiveness and Cost-Effectiveness Evidence section reports correlations between changes in bone turnover markers and BMD, including a statistically significant but weak correlation during teriparatide treatment. It also says not all correlations were significant and cautions that their usefulness varies by population. The review does not establish that markers predict the magnitude of BMD increases across FDA-approved therapies generally. (LLM, conf=0.84)
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
87 more claims · 25 with their cited sources checked
Create a free account to see all 132 claims and to verify the 18 references still open.
- Probably not a substantial claim. 26
- It may state two separate claims as one. 25
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“this equated to a health care cost of $1088”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Previous studies31,46,47,48 in emergency department patients have identified primarily benefits, including reductions in health care costs, medical retirement, and depressive symptoms.”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Experimental — accuracy not yet measuredIn the citing paper
“yielding an uptake of 89.9%”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
In the citing paper
“this issue was addressed by instead performing a thorough cost accounting from 2 specific exemplar interventions.30,31”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Diagnostic assessment
“Screening BMD and vertebral imaging recommendations for men are outlined in Table 8.”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Additional bone densitometry technologies
“Table: Table 8 Additional bone densitometry technologies”
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Incidence and Economic Burden of Osteoporosis-Related Fractures in the United States, 2005–2025
Burge, R., Dawson-Hughes, B., Solomon, D. H., Wong, J. B., King, A., & Tosteson, A. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.061113 · Cited by 4,026
Interventions for preventing falls in older people living in the community
Gillespie, L. D., Robertson, M. C., Gillespie, W. J., Sherrington, C., Gates, S., Clemson, L., & Lamb, S. E. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007146.pub3 · Cited by 3,966
Professor Kanis, J. A., Melton, L. J., Christiansen, C., Johnston, C. C., & Khaltaev, N. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090802 · Cited by 3,849
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489 · cited 1×
“by about 40 %, and nonvertebral fractures by about 20 % over 3 years [56].”
BackgroundDecreased bioavailability of vitamin D in obesity
Wortsman, J., Matsuoka, L. Y., Chen, T. C., Lu, Z., & Holick, M. F. (2000) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/72.3.690 · Cited by 3,204 · cited 1×
“This regimen should be followed by maintenance therapy of 1500–2000 IU/day or whatever dose is needed to maintain the target blood level [37, 38].”
Background
Research works printed but not linked: 4
- Office of the Surgeon General (US) (2004) Bone health and osteoporosis: a report of the Surgeon General. Office of the Surgeon General (US), Rockville (MD). Available from: http://www.ncbi.nlm.nih.gov/books/NBK45513/. Accessed March 2014 20945569
- National Osteoporosis Foundation Physician’s guide to prevention and treatment of osteoporosis 2005 Washington, DC National Osteoporosis Foundation
- Institute of Medicine (US) Committee to review dietary reference intakes for vitamin D and calcium (2011). In: Ross AC, Taylor CL, Yaktine AL et al (eds) Dietary reference intakes for calcium and vitamin D. National Academies Press (US), Washington (DC). Available from: http://www.ncbi.nlm.nih.gov/books/NBK56070/. Accessed March 2014 21796828
- Cummings, SR, San Martin J, McClung MR et al (2009) FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756–765. (Erratum in: N Engl J Med. 2009;36(10):191) 19671655 · DOI · Paper page
Cited by
Items 901–1,000 of 4,108
Sun, S., Sun, L., Kang, Y., Tang, L., Qin, Y., & Ta, D. (2019) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2019.08.025 · Cited by 31
Billington, E. O., Feasel, A. L., & Kline, G. A. (2019) · Journal of General Internal Medicine · doi:10.1007/s11606-019-05384-x · Cited by 30
Osteoporosis in Primary Biliary Cholangitis: Prevalence, Impact and Management Challenges
Trivedi, H. D., Danford, C. J., Goyes, D., & Bonder, A. (2020) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s204638 · Cited by 33
“In patients who are on treatment, repeat DEXA should be undergone every 1 to 2 years.(35)”
BackgroundLee, J., Alqudaihi, H., Kang, M. S., Kim, J., Lee, J. W., Ko, B. S., Son, B. H., Ahn, S. H., Lee, J. E., Han, S. W., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00366 · Cited by 28
Sietsema, D. L. (2020) · Nursing Clinics of North America · doi:10.1016/j.cnur.2020.02.002 · Cited by 36
Bar, M., Ott, S. M., Lewiecki, E. M., Sarafoglou, K., Wu, J. Y., Thompson, M., Vaux, J. J., Dean, D. R., Saag, K. G., Hashmi, S. K., et al. (2020) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2020.07.001 · Cited by 31
Self-citationDual-energy X-ray absorptiometry bone densitometry in pediatrics: a practical review and update
Khalatbari, H. K., Binkovitz, L. A., & Parisi, M. T. (2020) · Pediatric Radiology · doi:10.1007/s00247-020-04756-4 · Cited by 34
Rendina, D., D’Elia, L., Evangelista, M., FILIPPO, G. D., Giaquinto, A., Abate, V., Barone, B., Piccinocchi, G., Prezioso, D., & Strazzullo, P. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01428-w · Cited by 29
Liang, S., Ling, S., Du, R., Li, Y., Liu, C., Shi, J., Gao, J., Sun, W., Li, J., Zhong, G., et al. (2020) · Bone · doi:10.1016/j.bone.2020.115712 · Cited by 31
Evaluating the reliability and readability of online information on osteoporosis
Yurdakul, O. V., Kılıçoğlu, M. S., & Bağcıer, F. (2020) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000311 · Cited by 31
“It usually remains silent until the occurrence of fractures, which may cause secondary health problems, including death (2).”
BackgroundAir Pollutants Interaction and Gender Difference on Bone Mineral Density T-Score in Taiwanese Adults
Lin, Y., Wang, C.-F., Chiu, H., Lai, B.-C., Tu, H., Wu, P.-Y., Huang, J., & Chen, S. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17249165 · Cited by 30
“Lifestyle factors such as vitamin D deficiency, inadequate physical activity, low calcium intake, smoking, and alcohol abuse have been associated with an increased risk of osteoporosis and fractures [3].”
BackgroundManagement of osteoporosis in older men
Kaufman, J. (2021) · Aging Clinical and Experimental Research · doi:10.1007/s40520-021-01845-8 · Cited by 35
“Recommendations concerning indications for case finding by BMD screening vary according to local guidelines; both the Endocrine Society (USA) and National Osteoporosis Foundation (USA) propose to screen men 70 years or older or men 50–69 years with other risk factors [79, 80].”
BackgroundMethodInfluentialIs diabetes mellitus a risk factor for low bone density: a systematic review and meta-analysis
Qiu, J.-Y., Li, C., Dong, Z., & Wang, J. (2021) · BMC Endocrine Disorders · doi:10.1186/s12902-021-00728-3 · Cited by 34
“It has been reported that 50% of women and 20% of men over 50 years of age experience osteoporotic-related fracture, causing morbidity and mortality [2].”
BackgroundAgarwal, S. C. (2021) · American Journal of Human Biology · doi:10.1002/ajhb.23647 · Cited by 32
“The exact age of peak bone mass differs at various skeletal sites, but is thought to generally occur by 20–30 years of age (Cosman et al., 2014).”
BackgroundDueregger, A., Heidegger, I. M., Ofer, P., Perktold, B., Ramoner, R. E., Klocker, H., & Eder, I. E. (2014) · Nutrients · doi:10.3390/nu6104491 · Cited by 33
Miller, P. D., Recker, R. R., Harris, S. T., Silverman, S. L., Felsenberg, D., Reginster, J.-Y. L., Day, B.-M., Barr, C. E., & Masanauskaite, D. (2013) · Osteoporosis International · doi:10.1007/s00198-013-2518-z · Cited by 30
Hadji, P., Felsenberg, D., Amling, M., Hofbauer, L. C., Kandenwein, J. A., & Kurth, A. A. (2013) · Osteoporosis International · doi:10.1007/s00198-013-2515-2 · Cited by 28
Ioannidis, G., Pallan, S., Παπαϊωάννου, Α., Mulgund, M., Rios, L. P., Ma, J., Thabane, L., Davison, K. S., Josse, R. G., Kovács, C. S., et al. (2014) · Archives of Osteoporosis · doi:10.1007/s11657-013-0169-5 · Cited by 29
Osteoporosis Update From the 2010 Santa Fe Bone Symposium
Lewiecki, E. M., Bilezikian, J. P., Khosla, S., Marcus, R., McClung, M. R., Miller, P. D., Watts, N. B., & Maricic, M. J. (2011) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2010.12.001 · Cited by 30
Self-citationResults of a fracture liaison service on hip fracture patients in an open healthcare system
Cosman, F., Nicpon, K., & Nieves, J. W. (2016) · Aging Clinical and Experimental Research · doi:10.1007/s40520-016-0545-2 · Cited by 28
Self-citationSu, Y., Leung, J., Hans, D., Aubry‐Rozier, B., & Kwok, T. (2016) · Osteoporosis International · doi:10.1007/s00198-016-3785-2 · Cited by 30
Chin, K., Appel, L. J., & Michos, E. D. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0637-2 · Cited by 28
Geyer, C. (2016) · American Journal of Lifestyle Medicine · doi:10.1177/1559827616682938 · Cited by 31
Osteoporosis: a discussion on the past 5 years
Schweser, K. M., & Crist, B. D. (2017) · Current Reviews in Musculoskeletal Medicine · doi:10.1007/s12178-017-9410-y · Cited by 32
Marques, A., Lucas, R., Simões, E., Verstappen, S. M. M., Jacobs, J. W. G., & da Silva, J. A. P. (2017) · RMD Open · doi:10.1136/rmdopen-2017-000509 · Cited by 30
Vertebral Imaging in the Diagnosis of Osteoporosis: a Clinician’s Perspective
Chou, S. H.-H., & LeBoff, M. S. (2017) · Current Osteoporosis Reports · doi:10.1007/s11914-017-0404-x · Cited by 30
Self-citationMaso, E. D., Just, R., Hick, C. A., Christopoulos, A., Sexton, P. M., Wootten, D. L., & Furness, S. G. B. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.12.016 · Cited by 29
Dehydroepiandrosterone and Bone
Zhou, S., & Glowacki, J. (2018) · Vitamins and hormones · doi:10.1016/bs.vh.2018.01.005 · Cited by 33
Calcium and Vitamin D Supplementation. Myths and Realities with Regard to Cardiovascular Risk
Muscogiuri, G., Barrea, L., Altieri, B., Di Somma, C., Bhattoa, H. P., Laudisio, D., Duval, G. T., Pugliese, G., Annweiler, C., Orio, F., et al. (2019) · Current Vascular Pharmacology · doi:10.2174/1570161117666190408165805 · Cited by 27
Leslie, W. D., Schousboe, J. T., Morin, S. N., Martineau, P., Lix, L. M., Johansson, H., McCloskey, E. V., Harvey, N. C., & Kanis, J. A. (2020) · Archives of Osteoporosis · doi:10.1007/s11657-020-00773-w · Cited by 27
Disease-related factors associated with exercise adherence in postmenopausal women with osteoporosis
Macías‐Hernández, S. I., Loya-García, F., Mora, R. Z., Nava‐Bringas, T. I., & Morones-Alba, D. (2020) · Journal of Frailty Sarcopenia and Falls · doi:10.22540/jfsf-05-072 · Cited by 27
Biomarkers of Aging and Relevant Evaluation Techniques: A Comprehensive Review
Xue, T., Zhu, Z., Wang, L., Li, C., Sun, L., Wang, W., & Gong, W. (2024) · Aging and Disease · doi:10.14336/ad.2023.00808-1 · Cited by 63
“An osteoporosis determination is made once the T-score is less than or equal to -2.5 [127].”
BackgroundInfluentialPei, M., Li, J., McConda, D. B., Wen, S., Clovis, N. B., & Danley, S. S. (2015) · Bone · doi:10.1016/j.bone.2015.04.040 · Cited by 27
Fatores de risco para osteoporose em mulheres na pós-menopausa do sudeste brasileiro
Buttros, D. D. A. B., Nahás-Neto, J., Nahás, E. A. P., Cangussu, L. M., Barral, A. B. C. R., & Kawakami, M. S. (2011) · Revista Brasileira Ginecologia e Obstetrícia · doi:10.1590/s0100-72032011000600006 · Cited by 50
Partial proximal tibia fractures
Raschke, M. C. E. J., Kittl, C., & Domnick, C. (2017) · EFORT Open Reviews · doi:10.1302/2058-5241.2.160067 · Cited by 27
Yaprak, G., Gemici, C., Temizkan, Ş., Özdemir, S., Doğan, B. Ç., & Seseogullari, O. O. (2018) · BMC Cancer · doi:10.1186/s12885-018-4899-z · Cited by 27
Thongprayoon, C., Acharya, P. C., Aeddula, N. R., Torres‐Ortiz, A., Bathini, T. J., Sharma, K., Ungprasert, P., Watthanasuntorn, K., Suarez, M. L. G., Salim, S. A., et al. (2019) · Archives of Osteoporosis · doi:10.1007/s11657-019-0587-0 · Cited by 30
Binkley, N., Morin, S. N., Martineau, P., Lix, L. M., Hans, D. B., & Leslie, W. D. (2020) · Osteoporosis International · doi:10.1007/s00198-020-05576-w · Cited by 29
Chau, Y. T., Nashi, N., Law, L. S., et al. (2020) · Archives of Osteoporosis · doi:10.1007/s11657-020-00816-2 · Cited by 27
Idiopathic Osteoporosis and Nephrolithiasis: Two Sides of the Same Coin?
Rendina, D., FILIPPO, G. D., Iannuzzo, G., Abate, V., Strazzullo, P., & Falchetti, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218183 · Cited by 30
“With regard to pathogenic mechanisms, idiopathic osteoporosis a d nephrolithiasis re both multifactorial disorders and share common modifiable and non-modifiable causative factors (Figure 1) [2,10].”
BackgroundInfluentialCost-effectiveness of Screening for Osteoporosis in Older Men With a History of Falls
Ito, K. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.27584 · Cited by 26
Wu, Q. F., Nasoz, F., Jung, J.-Y., Bhattarai, B. D., Han, M., Greenes, R. A., & Saag, K. G. (2021) · Scientific Reports · doi:10.1038/s41598-021-83828-3 · Cited by 34
Iolascon, G., Alessandro de, S. I. R. E., Curci, C., Paoletta, M., Liguori, S., Calafiore, D., Gimigliano, F., & Moretti, A. (2021) · European Journal of Physical and Rehabilitation Medicine · doi:10.23736/s1973-9087.21.06581-3 · Cited by 30
Gao, C., Song, H., Chen, B., et al. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.684334 · Cited by 27
“However, DXA is only available in large general hospitals in China and limited by its inconvenience, professional operation and high cost; it may not be suitable for wide screening of osteoporosis (5, 6), especially in extensive rural areas of China.”
BackgroundWei, Z., Ge, F., Che, Y., Wu, S., Dong, X. W., & Song, D. (2021) · Biomolecules · doi:10.3390/biom12010041 · Cited by 33
Osteoporosis Diagnosis, Management, and Referral Practice After Fragility Fractures
Snodgrass, P., Zou, A., Gruntmanis, U., & Gitajn, I. L. (2022) · Current Osteoporosis Reports · doi:10.1007/s11914-022-00730-1 · Cited by 30
Recommendations by the Spanish Society of Rheumatology on Osteoporosis
Naranjo, A., Fontecha, P. D. D. C., Acín, M. P. A., Rodríguez, L. M. A., Casado, E., Castañeda, S., Aresté, J. F., Gifre, L., Vaquero, C. G., Rodríguez, G. C., et al. (2019) · Reumatología Clínica (English Edition) · doi:10.1016/j.reumae.2018.09.011 · Cited by 40
A Scoping Review of the Skeletal Effects of Naringenin
Muhamad, M. L. N., Ekeuku, S. O., Wong, S. K., & Chin, K. (2022) · Nutrients · doi:10.3390/nu14224851 · Cited by 27
Bisphosphonates for osteoporosis in people with cystic fibrosis
Jeffery, T. C., Chang, A. B., & Conwell, L. S. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002010.pub5 · Cited by 36
Xue, F., Ma, H., Stehman‐Breen, C. O., HALLER, C. A., Katz, L., Wagman, R. B., Critchlow, C. W., & for the Denosumab Global Safety Assessment Team (2013) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3477 · Cited by 28
Zhumkhawala, A.-A., Gleason, J. M., Cheetham, T. C., et al. (2013) · Urology · doi:10.1016/j.urology.2012.11.066 · Cited by 27
Profile of teriparatide in the management of postmenopausal osteoporosis
Sikon, A. L., & Batur (2010) · International Journal of Women s Health · doi:10.2147/ijwh.s4919 · Cited by 27
Zoledronic acid: clinical utility and patient considerations in osteoporosis and low bone mass
Hamdy, R. C. (2010) · Drug Design Development and Therapy · doi:10.2147/dddt.s6287 · Cited by 27
Hadji, P., Gamerdinger, D., Spieler, W., Kann, P. H., Loeffler, H., Articus, K., Moericke, R., & Ziller, V. (2011) · Osteoporosis International · doi:10.1007/s00198-011-1583-4 · Cited by 31
Hepatitis C virus coinfection as a risk factor for osteoporosis and fracture
Bedimo, R. G., Maalouf, N. M., & Re, V. L. (2016) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000259 · Cited by 28
Freund, O., Reychav, I., McHaney, R., Goland, E., & Azuri, J. (2017) · International Journal of Medical Informatics · doi:10.1016/j.ijmedinf.2017.02.012 · Cited by 31
Vranken, L., Wyers, C. E., van den Bergh, J. P., & Geusens, P. (2017) · Calcified Tissue International · doi:10.1007/s00223-017-0284-1 · Cited by 27
Shi, L., Gao, F., Sun, W., Wang, B., Guo, W., Cheng, L., Li, Z., & Wang, W. (2017) · Osteoporosis International · doi:10.1007/s00198-017-4136-7 · Cited by 27
Cherian, K. E., Kapoor, N., Shetty, S., et al. (2017) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2017.08.002 · Cited by 27
Competing Risks of Fracture and Death in Older Adults with Chronic Kidney Disease
Hall, R. K., Sloane, R. J., Pieper, C. F., Houtven, C. H. V., LaFleur, J., Adler, R. A., & Colon-Emeric, C. S. (2018) · Journal of the American Geriatrics Society · doi:10.1111/jgs.15256 · Cited by 34
Pinto, A. C. B. E., Siéssere, S., Calefi, A. P., de Oliveira, L. F. F., Ervolino, E., de Souza, S. L. S., Furlaneto, F. A. C., & Messora, M. R. (2019) · Clinical Oral Implants Research · doi:10.1111/clr.13503 · Cited by 28
Rühling, S., Schwarting, J., Froelich, M. F., Löffler, M. T., Bodden, J. H., Petzsche, M. R. H., Baum, T. H., Wostrack, M., Aftahy, A. K., Seifert‐Klauss, V., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1222041 · Cited by 29
“For the drug therapy options evaluated in this study, reductions in fractures and increases in BMD are best demonstrated over a period of approximately 3–5 years, and the likelihood of side effects or treatment failures was also reported to be the greatest during this period (29, 30).”
Challenges in implementing and maintaining osteoporosis therapy
Modi, A., Sajjan, S., & Gandhi, S. K. (2014) · International Journal of Women s Health · doi:10.2147/ijwh.s53489 · Cited by 33
Bone Density and Fractures in HIV-infected Postmenopausal Women: A Systematic Review
Cortés, Y. I., Yin, M. T., & Reame, N. K. (2015) · Journal of the Association of Nurses in AIDS Care · doi:10.1016/j.jana.2015.03.005 · Cited by 28
HIV Medications: An Update and Review of Metabolic Complications
Hester, E. K. (2012) · Nutrition in Clinical Practice · doi:10.1177/0884533611431985 · Cited by 28
Patients’ Response Toward an Automated Orthopedic Osteoporosis Intervention Program
Varacallo, M. A., Fox, E., Paul, E. M., Hassenbein, S. E., & Warlow, P. M. (2013) · Geriatric Orthopaedic Surgery & Rehabilitation · doi:10.1177/2151458513502039 · Cited by 26
Applying ethnic-specific bone mineral density T-scores to Chinese women in the USA
Lo, J. C.-M., Kim, S. J., Chandra, M., & Ettinger, B. B. (2016) · Osteoporosis International · doi:10.1007/s00198-016-3673-9 · Cited by 30
Combined Pharmacologic Therapy in Postmenopausal Osteoporosis
Shen, Y., Gray, D. L., & Martinez, D. S. (2016) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2016.09.008 · Cited by 27
Osteoporosis Prevention and Management
Pai, M. V. (2017) · The Journal of Obstetrics and Gynecology of India · doi:10.1007/s13224-017-0994-3 · Cited by 34
Quirós-Roldán, E., Brianese, N., Raffetti, E., Focà, E., Pezzoli, M. C., Bonito, A., Ferraresi, A., Lanza, P., Porcelli, T., & Castelli, F. (2017) · The Brazilian Journal of Infectious Diseases · doi:10.1016/j.bjid.2017.08.003 · Cited by 28
An Update on Menopause Management
Ward, K., & Deneris, A. (2018) · Journal of Midwifery & Women s Health · doi:10.1111/jmwh.12737 · Cited by 29
Bone-Modifying Agents in Early-Stage and Advanced Breast Cancer
Heeke, A. L., Nunes, M. R., & Lynce, F. C. (2018) · Current Breast Cancer Reports · doi:10.1007/s12609-018-0295-6 · Cited by 26
Risk factors for vertebral fracture in primary hyperparathyroidism
Liu, M., Williams, J. M., Kuo, J. H., Lee, J. A., Silverberg, S. J., & Walker, M. D. (2019) · Endocrine · doi:10.1007/s12020-019-02099-1 · Cited by 27
Chandran, M., Chin, Y. A., Choo, K. S., Ang, W. C., Huang, X. F., LIU, X., Tay, D., Aung, T., Ali, A., Thu, W. P. P., et al. (2020) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2020.04.001 · Cited by 26
“Organizations such as the National Osteoporosis Foundation [1], American Association of Clinical Endocrinologists [2] and the United States Preventive Task Force (USPTF) [3] recommend that all women aged 65 years and above should have a screening DXA.”
BackgroundRacial disparities, FRAX, and the care of patients with osteoporosis
Lewiecki, E. M., Wright, N. C., & Singer, A. J. (2020) · Osteoporosis International · doi:10.1007/s00198-020-05655-y · Cited by 26
Self-citationVitamin D supplementation in patients with cystic fibrosis: A systematic review and meta-analysis
Juhász, M. F., Varannai, O., Németh, D. I., Szakács, Z., Kiss, S., Izsák, V. D., Martonosi, Á. R., Hegyi, P. J., & Párniczky, A. (2020) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2020.12.008 · Cited by 29
Cost‐effectiveness of secondary fracture prevention intervention for Medicare beneficiaries
Nayak, S., Singer, A. J., & Greenspan, S. L. (2021) · Journal of the American Geriatrics Society · doi:10.1111/jgs.17381 · Cited by 29
Maleitzke, T., Hildebrandt, A., Dietrich, T., Appelt, J., Jahn, D., Otto, E., Zocholl, D., Baranowsky, A., Duda, G. N., Tsitsilonis, S., et al. (2021) · iScience · doi:10.1016/j.isci.2021.103689 · Cited by 28
“Pharmacologically employed CTR agonists, most commonly obtained from salmon or eel, exhibit a more than 50-fold higher potency than mammalian CT and have been approved by the FDA for hypercalcemic emergencies and osteoporosis treatment (Cosman et al., 2014).”
BackgroundA Traditional Chinese Medicine Plant Extract Prevents Alcohol-Induced Osteopenia
Qian, D., Zhou, H. C., Fan, P., Yu, T., Patel, A., O'Brien, M. A., Wang, Z., Lu, S., Tong, G., Shan, Y., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.754088 · Cited by 29
“Osteoporosis is the most common bone disease, representing a significant public health problem worldwide (Cosman et al., 2014; Wright et al., 2014; Zhou and Glowacki, 2017; Langdahl and Andersen, 2018; Zhou and Glowacki, 2018; Compston et al., 2019).”
Prevalence and treatment of fragility fractures in Spanish primary care: PREFRAOS study
Martínez-Laguna, D., Carbonell-Abella, C., Bastida, J.-C., González, M., Micó-Pérez, R. M., Vargas, F., Balcells, M., Canals, L., & on behalf of the PREFRAOS Group (2022) · Archives of Osteoporosis · doi:10.1007/s11657-022-01124-7 · Cited by 27
“National and international clinical practice guidelines [18, 19] recommend treatment in subjects with fragility fractures (major fractures), regardless of BMD, or a fragility fracture if bone mass is low (osteopenia), and subjects with osteoporotic BMD without fractures.”
BackgroundMills, E. S., Hah, R. J., Fresquez, Z. A., Mertz, K. C., Buser, Z., Alluri, R. K., & Anderson, P. A. (2022) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.22.00469 · Cited by 28
Ogiri, M., Nishida, K., Park, H., & Rossi, A. (2023) · Spine Surgery and Related Research · doi:10.22603/ssrr.2022-0198 · Cited by 28
Wang, C., Zheng, H. W., He, J.-W., Zhang, H., Yue, H., Hu, W.-W., Gu, J.-M., Shao, C., Fu, W.-Z., Hu, Y.-Q., et al. (2014) · The Pharmacogenomics Journal · doi:10.1038/tpj.2014.52 · Cited by 28
Kanis, J. А., McCloskey, E. V., Johansson, H., Ström, O., Borgström, F., & Odén, A. (2009) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2009.09.002 · Cited by 32
Bonaccorsi, G., Fila, E., Cervellati, C., et al. (2015) · Calcified Tissue International · doi:10.1007/s00223-015-0009-2 · Cited by 26
2008 Santa Fe Bone Symposium: update on osteoporosis.
Lewiecki, E., Baim, S., Bilezikian, J., Eastell, R., Leboff, M., & Miller, P. D. (2009) · Journal of clinical densitometry · doi:10.1016/j.jocd.2009.02.002 · Cited by 28
Self-citationBansal, S., Pecina, J. L., Merry, S. P., Kennel, K. A., Maxson, J. A., Quigg, S. M., & Thacher, T. D. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3026-0 · Cited by 27
Zhang, Z., Liao, E. Y., Xia, W., Lin, H. V., Cheng, Q., Wang, L., Hao, Y., Chen, D., Tang, H., Peng, Y., et al. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3141-y · Cited by 29
Laboratory testing for secondary osteoporosis evaluation
Adler, R. A. (2012) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2012.01.024 · Cited by 31
Imaging Findings in Eating Disorders
Kraeft, J. J., Uppot, R. N., & Heffess, A. M. (2013) · American Journal of Roentgenology · doi:10.2214/ajr.12.9641 · Cited by 26
da Silva, Y. B., Aguiar, L. B., Pinto-Neto, A. M., Baccaro, L. F., & Costa‐Paiva, L. (2016) · Archives of Osteoporosis · doi:10.1007/s11657-015-0255-y · Cited by 30
The effect of boron on alveolar bone loss in osteoporotic rats
Toker, H. Ç., Özdemir, H., Yüce, H. B., & Göze, F. (2016) · Journal of Dental Sciences · doi:10.1016/j.jds.2016.03.011 · Cited by 30
Özen, G., Kamen, D. L., Mikuls, T. R., England, B. R., Wolfe, F., & Michaud, K. D. (2018) · Arthritis Care & Research · doi:10.1002/acr.23331 · Cited by 31
Association between liver enzymes and bone mineral density in Koreans: a cross-sectional study
Do, H. J., Shin, J., Lee, J., Lee, Y. J., Kim, M.-R., Nam, D., Kim, E., Park, Y., Suhr, K., & Ha, I. (2018) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-018-2322-1 · Cited by 28
Cheng, L., Zhang, K., & Zhang, Z. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s179568 · Cited by 26
The Effects of Photobiomodulation on MC3T3-E1 Cells via 630 nm and 810 nm Light-Emitting Diode
Chang, B., Qiu, H., Zhao, H., Yang, X., Wang, Y., Ji, T., Zhang, Y., Quan, Q., Li, Y., Zeng, J., et al. (2019) · Medical Science Monitor · doi:10.12659/msm.920396 · Cited by 28
Zhang, F., Wang, Z., Su, H., Zhao, H., Lu, W. W., Zhou, W., & Zhang, H. (2022) · Osteoporosis International · doi:10.1007/s00198-022-06456-1 · Cited by 38
“5 SD) [26]; (2) age was range from 60 to 80 years; (3) participants received conventional treatment with anti-osteoporotic medications; and (4) no contraindications to exercise and not using assistive mobility devices, like crutches or wheelchair.”
BackgroundNian, S., Zhao, Y., Li, C., Zhu, K., Li, N., Li, W., & Chen, J. (2024) · The Spine Journal · doi:10.1016/j.spinee.2024.04.016 · Cited by 28
Hossen, M. S., Hoque, A., Islam, M. T., Kirawanich, P., Baharuddin, M. H., Alsaif, H., & Soliman, M. S. (2024) · IEEE Sensors Journal · doi:10.1109/jsen.2024.3459794 · Cited by 26
Nappo, K. E., Christensen, D. L., Wolfe, J. A., & Tintle, S. M. (2018) · Journal of Shoulder and Elbow Surgery · doi:10.1016/j.jse.2017.11.008 · Cited by 31
Metadata
- Authors
- Cosman, F., de Beur, S. J., LeBoff, M. S., Lewiecki, E. M., Tanner, B., Randall, S., & Lindsay, R.
- Affiliations
- Helen Hayes Hospital (US)
- Brigham and Women's Hospital (US)
- New Mexico Clinical Research & Osteoporosis Center (US)
- Bone Health and Osteoporosis Foundation (US)
- Corresponding author
- Cosman, F.
- Venue
- Osteoporosis International
- Published
- 2014-08-15
- Volume
- 25
- Issue
- 10
- Pages
- 2359-2381
- ISSN
- 0937-941X (ISSN-L)
- 1433-2965
- PMC
- PMC4176573
- OpenAlex
- W2171709369
- Semantic Scholar
- 91c0d02cdbd4c5dd69ed206e6a0b2b94c9aa0830
- Cited by
- 4,149
- References
- 101
- Citations by year
- 2026: 141 · 2025: 226 · 2024: 267 · 2023: 292 · 2022: 351 · 2021: 415 · 2020: 458 · 2019: 336 · 2018: 311 · 2017: 304 · 2016: 285 · 2015: 246 · 2014: 141
- FWCI
- 242.08
- Type
- journal article
- Language
- en
- Update notices
- correction (2015-05-19)
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Osteoporosis International (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Surgery › Hip and Femur Fractures
- Keywords
- osteoporosis, osteoporosis prevention, osteoporosis treatment, bone health, osteoporosis drugs
- MeSH terms
- Aged, Calcium, Dietary, Diet, Female, Humans, Male, Middle Aged, Osteoporosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.